![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AazeinTx has acquired all rights to NEO6860, a clinical-stage TRPV1 antagonist in adMare’s technology portfolio. With a team at the University of Calgary led by Dr. Richard Wilson AazeinTx proposes to bring a pill-based form of NEO6860.
Lead Product(s): NEO6860
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: NEO6860
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: AazeinTX
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 17, 2021
Details:
The parties have terminated the 2017 license agreement pursuant to which the Company had exclusive rights to develop and commercialize the BLU-5937 Assets and henceforth.
Lead Product(s): BLU-5937
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: BELLUS Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 23, 2020